← Shenyang Xingqi Pharmaceutical overview

Shenyang Xingqi Pharmaceutical vs Zhejiang Huahai Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Shenyang Xingqi Pharmaceutical Co Ltd (300573.CS)

Q3 202628 Jul – 11 Sep 2026

▲3

Xingqi's profit jumps, buyback done, pipeline advances despite new rival

First-half profit and dividend beat expectations Xingqi's first-half net profit rose 28.5% to 430 million yuan on 20.5% higher revenue, with an 82% gross margin. It will pay a cash dividend of 3 yuan per 10 shares, about 106 million yuan. Strong earnings and cash return support the stock price.
The interim results and dividend are the core new financial news that directly lift investor confidence and the stock's value.
Company completed 100 million yuan buyback in a week Xingqi finished its 80-100 million yuan share buyback plan in about a week, paying the full 100 million yuan by August 4. Buying back its own stock reduces shares outstanding and signals management's confidence, which tends to support the price.
The buyback is a concrete capital action that shows management's belief in the company and can lift the share price.
New eye-drop drug gets clinical trial approval Xingqi received NMPA approval to start clinical trials for SQ-23082 eye drops, a Class 2.1 modified new drug for allergic conjunctivitis itching. No similar product is sold in China or abroad, so success could open a new market and add future revenue.
This pipeline advance is new technology news that could expand Xingqi's product line and long-term growth.
Qilu's atropine application accepted, but Xingqi still leads Qilu Pharmaceutical's application for atropine sulfate eye drops was accepted, adding a potential rival in children's myopia. However, Xingqi remains the only approved product, with 2025 sales up 212% to 603.6 million yuan. Qilu's launch timing is uncertain, so the near-term threat is limited.
This is the main competitive development that could pressure future pricing, but Xingqi's first-mover advantage currently outweighs it.

August 202628 Jul – 11 Sep 2026

▲3

Xingqi's profit jumps, buyback done, pipeline advances despite new rival

First-half profit and dividend beat expectations Xingqi's first-half net profit rose 28.5% to 430 million yuan on 20.5% higher revenue, with an 82% gross margin. It will pay a cash dividend of 3 yuan per 10 shares, about 106 million yuan. Strong earnings and cash return support the stock price.
The interim results and dividend are the core new financial news that directly lift investor confidence and the stock's value.
Company completed 100 million yuan buyback in a week Xingqi finished its 80-100 million yuan share buyback plan in about a week, paying the full 100 million yuan by August 4. Buying back its own stock reduces shares outstanding and signals management's confidence, which tends to support the price.
The buyback is a concrete capital action that shows management's belief in the company and can lift the share price.
New eye-drop drug gets clinical trial approval Xingqi received NMPA approval to start clinical trials for SQ-23082 eye drops, a Class 2.1 modified new drug for allergic conjunctivitis itching. No similar product is sold in China or abroad, so success could open a new market and add future revenue.
This pipeline advance is new technology news that could expand Xingqi's product line and long-term growth.
Qilu's atropine application accepted, but Xingqi still leads Qilu Pharmaceutical's application for atropine sulfate eye drops was accepted, adding a potential rival in children's myopia. However, Xingqi remains the only approved product, with 2025 sales up 212% to 603.6 million yuan. Qilu's launch timing is uncertain, so the near-term threat is limited.
This is the main competitive development that could pressure future pricing, but Xingqi's first-mover advantage currently outweighs it.

Latest28 Jul – 11 Sep 2026

▲3

Xingqi's profit jumps, buyback done, pipeline advances despite new rival

First-half profit and dividend beat expectations Xingqi's first-half net profit rose 28.5% to 430 million yuan on 20.5% higher revenue, with an 82% gross margin. It will pay a cash dividend of 3 yuan per 10 shares, about 106 million yuan. Strong earnings and cash return support the stock price.
The interim results and dividend are the core new financial news that directly lift investor confidence and the stock's value.
Company completed 100 million yuan buyback in a week Xingqi finished its 80-100 million yuan share buyback plan in about a week, paying the full 100 million yuan by August 4. Buying back its own stock reduces shares outstanding and signals management's confidence, which tends to support the price.
The buyback is a concrete capital action that shows management's belief in the company and can lift the share price.
New eye-drop drug gets clinical trial approval Xingqi received NMPA approval to start clinical trials for SQ-23082 eye drops, a Class 2.1 modified new drug for allergic conjunctivitis itching. No similar product is sold in China or abroad, so success could open a new market and add future revenue.
This pipeline advance is new technology news that could expand Xingqi's product line and long-term growth.
Qilu's atropine application accepted, but Xingqi still leads Qilu Pharmaceutical's application for atropine sulfate eye drops was accepted, adding a potential rival in children's myopia. However, Xingqi remains the only approved product, with 2025 sales up 212% to 603.6 million yuan. Qilu's launch timing is uncertain, so the near-term threat is limited.
This is the main competitive development that could pressure future pricing, but Xingqi's first-mover advantage currently outweighs it.

Zhejiang Huahai Pharmaceutical Co Ltd (600521.CG)

Q3 202624 Jul – 7 Oct 2026

▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.
This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.
Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.
A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.
Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.
Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.
US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.
These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.

August 202624 Jul – 7 Oct 2026

▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.
This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.
Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.
A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.
Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.
Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.
US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.
These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.

Latest24 Jul – 7 Oct 2026

▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.
This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.
Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.
A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.
Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.
Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.
US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.
These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.